Seelos Therapeutics (SEEL) Now Covered by Analysts at Roth Capital

Share on StockTwits

Roth Capital started coverage on shares of Seelos Therapeutics (NASDAQ:SEEL) in a report released on Tuesday, BenzingaRatingsTable reports. The firm issued a buy rating and a $8.00 target price on the stock.

Separately, HC Wainwright assumed coverage on shares of Seelos Therapeutics in a research note on Friday, May 10th. They set a buy rating and a $4.00 price objective on the stock.

SEEL traded down $0.04 on Tuesday, hitting $2.73. 1,455 shares of the company’s stock were exchanged, compared to its average volume of 612,950. Seelos Therapeutics has a twelve month low of $1.32 and a twelve month high of $17.40.

Several large investors have recently made changes to their positions in the business. Jane Street Group LLC acquired a new stake in shares of Seelos Therapeutics during the 1st quarter valued at $168,000. Oxford Asset Management LLP acquired a new stake in shares of Seelos Therapeutics during the 1st quarter valued at $54,000. Renaissance Technologies LLC acquired a new stake in shares of Seelos Therapeutics during the 1st quarter valued at $1,602,000. Finally, BlackRock Inc. acquired a new stake in shares of Seelos Therapeutics during the 1st quarter valued at $908,000. Institutional investors own 28.12% of the company’s stock.

Seelos Therapeutics Company Profile

Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients.

Further Reading: What is a Derivative?

Receive News & Ratings for Seelos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seelos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.